The company inked an exclusive distribution agreement in Australia with AMSL Diabetes earlier this year.
According to the terms of the deal, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing. AMSL Diabetes will take over the sales, marketing and distribution activities for the V-Go device in Australia.
“We are pleased to announce V-Go wearable insulin delivery device is now available for patients with Type 2 diabetes in Australia,” Valeritas CEO John Timberlake said in prepared remarks. “Australia is the second and largest country outside of the United States in which our flagship product V-Go has been launched, and we are excited V-Go will be demonstrated to physicians and patients during the Australia Diabetes Society meeting in Adelaide this week.”
Also this month, Valeritas launched its V-Go device in New Zealand thanks to a distro deal with NZMS Diabetes.